HK Inno.N Corp banner
H

HK Inno.N Corp
KOSDAQ:195940

Watchlist Manager
HK Inno.N Corp
KOSDAQ:195940
Watchlist
Price: 54 500 KRW 3.61%
Market Cap: ₩1.5T

P/B

1.2
Current
28%
More Expensive
vs 3-y average of 0.9

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
1.2
=
Market Cap
₩1.6T
/
Total Equity
₩1.3T

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
1.2
=
Market Cap
₩1.6T
/
Total Equity
₩1.3T

Valuation Scenarios

HK Inno.N Corp is trading above its 3-year average

If P/B returns to its 3-Year Average (0.9), the stock would be worth ₩42 432.87 (22% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-22%
Maximum Upside
+1%
Average Downside
12%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 1.2 ₩54 500
0%
3-Year Average 0.9 ₩42 432.87
-22%
5-Year Average 1 ₩44 072.76
-19%
Industry Average 1.2 ₩54 888.47
+1%
Country Average 1.1 ₩51 236.19
-6%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
KR
HK Inno.N Corp
KOSDAQ:195940
1.5T KRW 1.2 23
US
Eli Lilly and Co
NYSE:LLY
820.3B USD 30.9 39.7
US
Johnson & Johnson
NYSE:JNJ
542.6B USD 6.7 25.8
CH
Roche Holding AG
SIX:ROG
248.4B CHF 7.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.7B GBP 5.9 28.1
CH
Novartis AG
SIX:NOVN
218.2B CHF 5.9 19.6
US
Merck & Co Inc
NYSE:MRK
272.8B USD 5.2 14.9
IE
Endo International PLC
LSE:0Y5F
244.4B USD -58.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 6 11.4
US
Pfizer Inc
NYSE:PFE
152.3B USD 1.8 19.6
US
Bristol-Myers Squibb Co
NYSE:BMY
116.3B USD 6.3 16.5
P/E Multiple
Earnings Growth PEG
KR
H
HK Inno.N Corp
KOSDAQ:195940
Average P/E: 21.9
23
22%
1
US
Eli Lilly and Co
NYSE:LLY
39.7
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
25.8
8%
3.2
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28.1
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
14.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.5
16%
1

Market Distribution

In line with most companies in Korea
Percentile
52st
Based on 1 345 companies
52st percentile
1.2
Low
0.1 — 0.7
Typical Range
0.7 — 2.3
High
2.3 —
Distribution Statistics
Korea
Min 0.1
30th Percentile 0.7
Median 1.1
70th Percentile 2.3
Max 2 461.2

HK Inno.N Corp
Glance View

Market Cap
1.5T KRW
Industry
Pharmaceuticals

HK inno.N Corp. engages in the provision of healthcare services. The company is headquartered in Chungju, Chungcheongbuk-Do. The company went IPO on 2021-08-09. The firm operates its business through three segments. The Prescription Drug segment is engaged in the manufacture and sale of hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, the circulatory system and others. The Health Beauty and Beverage (HB&B) segment is engaged in the manufacture and sale of products such as hangover relieving products, as well as health drinks and food products. The Other segment is engaged in the trademark royalties business and other services. The firm sells its products within domestic market and to overseas markets.

Intrinsic Value
58 926.6 KRW
Undervaluation 8%
Intrinsic Value
Price ₩54 500
H
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett